STOCK TITAN

GLOBESTAR THERAPEUTICS CO - $GSTC STOCK NEWS

Welcome to our dedicated page for GLOBESTAR THERAPEUTICS CO news (Ticker: $GSTC), a resource for investors and traders seeking the latest updates and insights on GLOBESTAR THERAPEUTICS CO stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GLOBESTAR THERAPEUTICS CO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GLOBESTAR THERAPEUTICS CO's position in the market.

Rhea-AI Summary
GlobeStar Therapeutics (GSTC) released its fiscal year first quarter financials, reporting $42,800 cash used in operating activities, a net loss per share of $0.00, and increased operating expenses. The company is focused on advancing Project Amethyst™, a compound for neurodegeneration from MS, and arranging financing for a pharmacokinetic study and clinical trial. GlobeStar aims for regulatory approvals and commercialization in multiple regions, aiming to tap into the growing global market for neurological disorders treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.75%
Tags
none
-
Rhea-AI Summary
GlobeStar Therapeutics Corporation has entered into an agreement with Advanced Innovative Partners (AIP) to provide advice and assistance for the development of Project Amethyst™, a compound intended to treat neurodegeneration from multiple sclerosis (MS). AIP will contribute to the refinement, approval, and launch of the therapy. The agreement has been approved by both parties and AIP will initially advise on the design and launch of an initial clinical trial in India. The reported incidence of MS has increased by approximately 50% in the 81 most affected countries between 2013 and 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.39%
Tags
-
Rhea-AI Summary
GlobeStar Therapeutics partners with SMI HealthCare to manage clinical trial and distribution of its Multiple Sclerosis treatment in India, Southeast Asia, Africa, and the Middle East (excluding Israel and Iraq).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
GLOBESTAR THERAPEUTICS CO

OTC:GSTC

GSTC Rankings

GSTC Stock Data

930.34k
1.08B
7.45%
0.01%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
United States of America
Richland